Search

Displaying results 4561 - 4570 of 7452 in total
  1. Drug

    PLG-0206

    go.drugbank.com/drugs/DB18116
    Investigational

    PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.[L48106]

  2. Drug

    Beludavimab

    go.drugbank.com/drugs/DB18952
    Investigational

    Beludavimab is under investigation in clinical trial NCT04746183 (AGILE (Early Phase Platform Trial for COVID-19)).

  3. Drug

    Neodymium

    go.drugbank.com/drugs/DB15318
    Experimental

    Neodymium is under investigation in clinical trial NCT03525522 (Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus).

  4. Drug

    Avotermin

    go.drugbank.com/drugs/DB11955
    Investigational

    Juvista has been investigated for the treatment, prevention, and basic science of Scars, Keloid, and Cicatrix.

  5. Drug

    Bradykinin

    go.drugbank.com/drugs/DB12126
    Investigational

    Bradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.

  6. Drug

    Ketanserin

    go.drugbank.com/drugs/DB12465
    Investigational

    Ketanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.

  7. Drug

    Irosustat

    go.drugbank.com/drugs/DB02292
    Investigational

    Irosustat has been investigated for the treatment of Metastatic Breast Cancer and Locally Advanced Breast Cancer.

  8. Drug

    Antipain

    go.drugbank.com/drugs/DB15251
    Experimental

    [A214481] Early studies investigated the potential for antipain to alter DNA damage and chromosomal aberrations in irradiated cells or those treated with chemical mutagens such as _N_-methyl-_N_'-nitro … [A214490] The binding of antipain to OPB has been used in molecular dynamic studies to identify other OPB inhibitors with more favourable pharmacodynamic and pharmacokinetic properties for potential development

  9. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

  10. Drug

    Famtozinameran

    go.drugbank.com/drugs/DB17088
    ApprovedInvestigational

    It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]